Statistical analysis for clinical trials
A pharmaceutical company needed statistical analysis and regulatory compliance across FDA and European frameworks to enter new markets. Umbizo supplied trial design, adaptive methodology, a statistical analysis plan, and an interim analysis of pilot data.
The challenge
The company needed robust statistical analysis and compliance across several jurisdictions to enter new markets. It required expertise in trial design, analysis, and approval processes that would satisfy both FDA and European regulatory requirements.
What we set out to do
- Develop a comprehensive statistical analysis plan consistent with the existing IRB
- Use pilot data to run an interim analysis
- Adapt the design if needed to reach a sufficient sample size
Our approach
Trial design optimisation
Developed adaptive trial methodology, performed power calculations and sample size determination, carried out protocol development and refinement, and assessed data quality.
Statistical implementation
Developed the Statistical Analysis Plan (SAP) and ran an interim quantitative analysis of efficacy and sample size.
Results and impact
The engagement delivered a 50% reduction in preliminary analysis time. It also streamlined the pathway to approval, enhanced data quality, enabled timely intervention on data collection issues in the early stages, accelerated market access, and supported robust regulatory compliance.
“Umbizo's statistical expertise and regulatory knowledge proved invaluable for our multinational trials. Their adaptive trial designs and analysis capabilities significantly reduced our time to market.”
Timeline
- Statistical Analysis Plan: 1 month
- Pilot analysis and interim report: 3 weeks
- Ongoing: preparations for longitudinal data and a final statistical analysis report
Looking forward
Expanding adaptive trial methodologies and developing automated statistical analysis tools for complex trial designs.
